Long‑Term Efficacy of Lecanemab in Early Alzheimer’s Disease: Findings from the Phase 3 Clarity AD Study

Eisai Co. Ltd. and its partner Biogen announced the long‑term results of the Phase 3 Clarity AD study and its extension at the 19th Clinical Trials on Alzheimer’s Disease conference. The data demonstrate that continuous treatment with lecanemab (marketed as LEQEMBI®) yields progressively greater clinical benefit for patients diagnosed with early Alzheimer’s disease.

Study Design and Population

  • Phase 3 Clarity AD: Randomized, double‑blind, placebo‑controlled trial assessing the effect of lecanemab on cognitive and functional decline.
  • Extension Phase: Patients who completed the core study were offered open‑label continuation of lecanemab.
  • Participants: Individuals with early Alzheimer’s disease, defined by clinical criteria and biomarker confirmation (amyloid‑positive status).

The extension provided a unique opportunity to observe treatment effects over a five‑year period, a duration rarely achievable in Alzheimer’s disease trials.

Key Clinical Outcomes

Metric5‑Year Cohort (LEQEMBI)Historical Reference Cohort
Relative risk of disease progressionMarkedly reducedBaseline
Decline in CDR‑SB scoresSteady decrease, plateauing after year 3Continuous decline
Cognitive/functional improvementObserved in a substantial proportion of low‑tau patientsNo improvement reported

The Clinical Dementia Rating – Sum of Boxes (CDR‑SB) scale, a validated tool for assessing cognitive‑functional impairment, showed a consistent reduction in decline among patients who remained on therapy for five years. Notably, patients with low tau protein levels—an emerging biomarker of disease severity—exhibited no decline, and in some cases, improvement in cognition and daily functioning.

Safety Profile

No new safety concerns emerged during the extended follow‑up. The safety data remained consistent with the findings from the core study, reinforcing the tolerability of long‑term lecanemab therapy.

Strategic Implications

  1. Early, Sustained Intervention The results underscore the clinical strategy of initiating treatment early in the disease course and maintaining therapy over several years. By slowing the progression of cognitive and functional decline, lecanemab may shift the disease trajectory and improve long‑term outcomes for patients.

  2. Regulatory and Commercial Development The positive long‑term efficacy and safety profile support ongoing regulatory submissions and market launch plans. Demonstrating sustained benefit over five years strengthens the evidence base required by regulatory agencies and payers.

  3. Broader Economic and Healthcare Context Alzheimer’s disease imposes significant economic burdens on healthcare systems worldwide. Therapies that delay functional decline can potentially reduce costs associated with caregiving, institutional care, and disease‑related comorbidities. The findings may influence reimbursement policies and healthcare resource allocation.

Cross‑Sector Insights

The success of lecanemab in the neurodegenerative space highlights broader industry trends:

  • Precision Medicine: The stratification of patients by tau levels mirrors approaches in oncology and cardiology, where biomarker‑guided therapies are increasingly standard.
  • Longitudinal Data Collection: The ability to track patient outcomes over multiple years aligns with data‑driven decision making in pharma and healthcare IT.
  • Patient‑Centric Outcomes: Emphasizing real‑world functional gains reflects a growing shift toward patient‑reported outcomes across therapeutic areas.

Conclusion

Eisai and Biogen’s long‑term data for lecanemab reinforce the therapeutic paradigm of early, continuous treatment for Alzheimer’s disease. The findings provide robust clinical evidence that may accelerate regulatory approval, influence reimbursement decisions, and ultimately improve patient care while aligning with broader economic imperatives in healthcare.